Fibrinogen-to-Albumin Ratio for Predicting Adverse Perinatal Outcomes in Preeclampsia

A dual-center retrospective cohort study of 924 preeclamptic patients from two tertiary hospitals. The dataset was used to evaluate the incremental prognostic value of the fibrinogen-to-albumin ratio for a composite adverse perinatal outcome. The study was authored by Xiaoyun Chen and last updated on 2026-05-29.

Use Cases

• Validating the incremental prognostic value of the fibrinogen-to-albumin ratio (FAR) for adverse perinatal outcomes based on the study's model performance metrics.
• Training logistic regression models for risk stratification in preeclampsia using the described composite outcome and candidate predictors.
• Benchmarking model performance using area under the curve (AUC), net reclassification improvement (NRI), and integrated discrimination improvement (IDI) as described in the results.
• Guiding anesthesia-relevant clinical decisions based on the identified FAR cutoff of 0.135 for coagulopathy and inflammation risk.

Strengths

• Dataset includes 924 patient records from two independent centers, enabling internal and external validation.
• Model performance is rigorously quantified with an AUC of 0.888 in the training cohort and 0.856 in external validation.
• Study reports specific incremental value metrics, including a continuous NRI of 0.397 and an IDI of 0.022.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count for the underlying data tables is unknown, which may limit suitability assessment.
• Data may reflect geographic or institutional bias inherent to the two specific tertiary referral hospitals.

Provenance

Source

figshare, authored by Xiaoyun Chen.

Collection Method

Dual-center retrospective cohort study.

Freshness

Last updated 2026-05-29 04:50:31; freshness should be verified.

Geography

Patients from two tertiary referral hospitals (centers A and B).